Evidence map›Paper›PMID 41103911›Full record

ReviewFrontiers in chemistry2025

Comprehensive medicinal chemistry survey highlights a portfolio of lead molecules for Alzheimer's disease therapy.

Pravin R Bhansali, Shashank M Sonkusare, Shubhangi S Savale, Yasanandana S Wijayasinghe, Yini Liao, Douglas C Sloan, Ganesh U Chaturbhuj, Brian S Muntean

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pravin R Bhansali *Department of Science, Faculty of Science and Technology, Alliance University, Bengaluru, Karnataka, India.
Shashank M Sonkusare *Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra, India.
Shubhangi S Savale *Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra, India.
Yasanandana S WijayasingheDepartment of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, United States.
Yini LiaoDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Douglas C SloanDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States.
Ganesh U ChaturbhujDepartment of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra, India.
Brian S Muntean *Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The World Health Organization reports 10 million new patients with dementia each year. The most common form of dementia is Alzheimer's disease (AD), which constitutes up to 70% of cases. AD is mainly characterized by loss of memory, which, in addition to its debilitating individual effect, represents a burden of 1.3 trillion US dollars globally. The staggering scale of hardship has spurred intense investigations from the scientific community in search of therapeutic solutions. Recent advances to combat AD involve the identification of numerous neural targets and concomitant chemical interventions as nodes of therapy. Due to disparate biological and chemical facets of AD therapy, a comprehensive perspective covering both arenas is currently missing from the literature. This perspective aims to provide an extensive understanding of anti-AD mechanics alongside small-molecule drug design efforts from a medicinal chemist viewpoint. We are confident that this survey of the literature will provide a resourceful motivation to propel future research efforts towards successful Alzheimer's disease therapy.

Indexed as

Alzheimer’s diseasedementia treatmentdrug designmedicinal chemistryneurobiology of disease

Identifiers

PMID41103911
PMCPMC12521189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.